OBJETIVOS: Correlacionar o nível de expressão das proteínas reguladoras do complemento (Cregs) CD55, CD59, CD35 e CD46 nos linfócitos B em uma coorte de pacientes com artrite reumatoide (AR) iniciando terapia com rituximabe (RTX) com a depleção e tempo de repopulação destas células no sangue periférico, associando, ainda, o nível de expressão destas proteínas à resposta clínica conforme os critérios do Colégio Americano de Reumatologia (ACR). MÉTODOS: Dez pacientes com AR receberam duas infusões de RTX 1g separadas por intervalo de 14 dias. Análises imunofenotípicas para detecção de CD19, CD55, CD59, CD35 e CD46 foram realizadas pré-infusão e após 1, 2, 6, 12, 18 e 24 meses ou até recaída clínica. Depleção de linfócitos B no sangue periférico foi definida como valor de CD19 menor que 0,005x109/l no total de leucócitos. Resposta ACR20 em 6 meses foi considerada positiva e recaída clínica foi definida como perda dessa resposta. A não obtenção de ACR20 em 6 meses foi considerada falha de resposta ao tratamento. RESULTADOS: Dez mulheres com mediana de 49 anos e DAS28 basal de 5,6; nove delas soropositivas para fator reumatoide foram acompanhadas. Repopulação de linfócitos B ocorreu em 2 meses em cinco pacientes e em 6 meses nas demais. Houve correlação entre o nível de expressão basal de CD46 com o tempo de repopulação (coeficiente de correlação de -0,733, p=0,016). Tendência semelhante foi detectada com CD35, porém sem significância estatística (coeficiente de correlação de -0,522, p=0,12). Não houve associação entre resposta clínica e expressão das proteínas regulatórias do complemento. CONCLUSÕES: Expressão aumentada de CD46 foi preditora de repopulação mais precoce de linfócitos B em pacientes com AR tratados com RTX. Estudos com amostras maiores serão necessários para avaliar associação das demais Cregs. / OBJECTIVES: To correlate the level of expression of the complement regulatory proteins (Cregs) CD55, CD59, CD35, and CD46 on B cells from a cohort of 10 patients with rheumatoid arthritis (RA) initiating treatment with rituximab (RTX) with the depletion and time of repopulation of these cells in peripheral blood, additionally correlating the level of expression of these proteins to clinical response according to the criteria of the American College of Rheumatology (ACR). METHODS: Ten patients with RA received two 1g RTX infusions within 14 day intervals. Immunophenotype analyses for CD19, CD55, CD59, CD35 and CD46 were performed before the infusion and at 1, 2, 6, 12, 18 and 24 months or until recurrence. Depletion of B cells on peripheral blood was defined as the CD19 count < 0.005x109/l. ACR20 at 6 months was considered a good clinical response and recurrence was defined as loss of this response. RESULTS: Ten women with median age of 49 years and basal DAS28 of 5.6 were monitored; 9 were seropositive for rheumatoid factor. Repopulation of B cells occurred within 2 months in 5 patients and within 6 months in the remaining women. There was correlation between the basal level of CD46 expression and the time to achieve repopulation (correlation coefficient -0.733, p=0.016). A similar trend was observed with the CD35, but without statistical significance (correlation coefficient - 0.522, p=012). There was no association between clinical response and the complement regulatory proteins. CONCLUSIONS: Increased CD46 expression predicted earlier repopulation of B cells in RA patients treated with RTX. Studies with larger samples are necessary to assess the association with the other Cregs.

Chimeric antigen receptors (CARs) are artificial molecules composed of an antibody derived antigen recognition domain which is fused with the signal transduction domain derived from the physiological TCR. CAR technology used to transduce patients T-cells and endow them with the specificity to a certain surface antigen, has been a major breakthrough in cancer immunotherapy in the last decade. This strategy has been most successful for treating hematologic malignancies. Various CAR approaches and applications are currently tested mainly in the United States where many clinical trials have been launched. In contrast, in the Czech Republic, there are only a few teams focused on this topic with no clinical trials going on. During my work on this diploma thesis and in close collaboration with MUDr. Pavel Otáhal, PhD., who is working on implementation of CAR technology into the Czech clinics for the treatment of B-cell malignancies, individual functional CARs were prepared and tested. CAR expressing Jurkat T-cell lines were generated using a lentiviral vector transduction system. CAR functionality was determined by two different assays. We have shown that individual CARs are able to recognize the B-cell lineage specific antigens CD19 and CD20 and significantly up-regulate the activation molecule CD69 upon...

Introdução: O fragmento C4d e os anticorpos anti-HLA doador específicos (DSA) são marcadores de resposta humoral em enxertos renais com rejeição, mas o papel das células B nesse processo ainda não é claro. Neste estudo foi avaliada a correlação entre C4d, DSA e células B de enxertos com disfunção e sua associação com aspectos morfológicos, função e sobrevida do rim transplantado. Material e Métodos: A marcação para C4d, células B CD20+ e plasmócitos CD138+ foi realizada por imunoperoxidase em biópsias por indicação de 110 receptores de transplante renal. Positividade para CD20 e CD138 foi definida por curva ROC (≥5 céls./mm2). O soro coletado concomitante a biópsia foi testado para DSA classe I e classe II. Estes marcadores foram correlacionados com dados clínicos e do transplante, a histopatologia de Banff e a evolução do rim transplantado. Resultados: Depósitos de C4d e DSA circulantes foram detectados em 100% e 70% dos pacientes com rejeição mediada por anticorpos (RMA) respectivamente, e nos casos de rejeição aguda celular (RAC) em 42% (p<0,001, vs. RMA) e 28% (p=0,003, vs. RMA). Estes dois marcadores correlacionaram-se positivamente (r=0,31, p=0,016). Houve correlação significativa entre DSA e plasmócitos CD138+ (r=0.32 p=0,006), mas as células CD20 e CD138 não se correlacionaram entre si. As células CD138+ predominaram na RMA, associadas com maior painel pré-transplante e DSA, mas não a C4d, e as células CD20+ predominaram na RAC e nas biópsias com fibrose intersticial/atrofia tubular, associadas a maior incompatibilidade HLA e a retransplantes. Pacientes com C4d+ tiveram pior função e sobrevida do enxerto em três anos de transplante, e aqueles com DSA+ uma pior 7 sobrevida do enxerto. Positividade para CD20 ou CD138 não foi preditiva da função ou sobrevida do enxerto. Na análise multivariada, somente o C4d foi fator de risco para perda do enxerto. Conclusões: Esses resultados confirmam o valor prognóstico do C4d e dos DSA para uma pior evolução do enxerto renal, e sugerem uma associação das células B CD20+ com parâmetros de rejeição celular e dos plasmócitos CD138+ com marcadores de resposta humoral. Entretanto, nesse estudo o infiltrado de células B na biópsia do enxerto não foi preditivo de uma pior evolução do rim transplantado. / Introduction: The fragment C4d and the donor specific anti-HLA antibodies (DSA) are markers of the humoral response in rejecting kidney grafts, but the role of B cells in this process is still unclear. In this study we evaluated the correlation between C4d, DSA and B cells in dysfunctional grafts, and their association with morphological features, and graft function and survival. Material and Methods: The staining for C4d, CD20+ B cells and CD138+ plasmocytes were done by immunoperoxidase in 110 kidney graft biopsies for cause. Positivity for CD20 and CD138 were established by ROC curve (≥5 cells/mm2). Serum collected at biopsy were tested for anti-HLA class I and II antibodies. These markers were correlated with clinical and transplant characteristics, Banff histopathology and graft outcomes. Results: C4d deposits and circulating DSA were detected in 100% and 70% of the patients with antibody-mediated rejection (AMR) respectively, and in cases with acute cellular rejection (ACR) in 42% (p<0.001, vs. AMR) and 28% (p=0.003, vs. AMR), respectively. Both markers were positively correlated (r=0.31, p=0.016), and there was also a significant correlation between DSA and plasmocytes CD138+ (r=0.32 p=0.006). CD20 and C138 cells were not siginificantly correlated. Plasmocytes CD138+ predominated in AMR, and were associated with higher pre transplant PRA and DSA positivity, but not with C4d. CD20+ B cells were highly expressed in ACR and in biopsies with interstitial fibrosis and tubular atrophy, in association with more HLA mismatches and re-transplants. Patients with C4d had poorer graft function and survival, and those 9 with DSA + also had a worse graft survival in three years of transplant. CD20 or CD138 cells were not predictive of graft outcomes. In multivariated analysis, only C4d remained a risk factor for graft loss. Conclusion: These results confirm the prognostic value of C4d and circulating DSA for a worse kidney graft outcome, and suggest an association of CD20+ B cells with parameters of cellular rejection whereas CD138+ plasmocytes correlated with markers of the humoral response. However, in this study the B cell infiltrate in graft biopsy was not predictive of adverse outcomes to the transplanted kidney.

Introdução: O fragmento C4d e os anticorpos anti-HLA doador específicos (DSA) são marcadores de resposta humoral em enxertos renais com rejeição, mas o papel das células B nesse processo ainda não é claro. Neste estudo foi avaliada a correlação entre C4d, DSA e células B de enxertos com disfunção e sua associação com aspectos morfológicos, função e sobrevida do rim transplantado. Material e Métodos: A marcação para C4d, células B CD20+ e plasmócitos CD138+ foi realizada por imunoperoxidase em biópsias por indicação de 110 receptores de transplante renal. Positividade para CD20 e CD138 foi definida por curva ROC (≥5 céls./mm2). O soro coletado concomitante a biópsia foi testado para DSA classe I e classe II. Estes marcadores foram correlacionados com dados clínicos e do transplante, a histopatologia de Banff e a evolução do rim transplantado. Resultados: Depósitos de C4d e DSA circulantes foram detectados em 100% e 70% dos pacientes com rejeição mediada por anticorpos (RMA) respectivamente, e nos casos de rejeição aguda celular (RAC) em 42% (p<0,001, vs. RMA) e 28% (p=0,003, vs. RMA). Estes dois marcadores correlacionaram-se positivamente (r=0,31, p=0,016). Houve correlação significativa entre DSA e plasmócitos CD138+ (r=0.32 p=0,006), mas as células CD20 e CD138 não se correlacionaram entre si. As células CD138+ predominaram na RMA, associadas com maior painel pré-transplante e DSA, mas não a C4d, e as células CD20+ predominaram na RAC e nas biópsias com fibrose intersticial/atrofia tubular, associadas a maior incompatibilidade HLA e a retransplantes. Pacientes com C4d+ tiveram pior função e sobrevida do enxerto em três anos de transplante, e aqueles com DSA+ uma pior 7 sobrevida do enxerto. Positividade para CD20 ou CD138 não foi preditiva da função ou sobrevida do enxerto. Na análise multivariada, somente o C4d foi fator de risco para perda do enxerto. Conclusões: Esses resultados confirmam o valor prognóstico do C4d e dos DSA para uma pior evolução do enxerto renal, e sugerem uma associação das células B CD20+ com parâmetros de rejeição celular e dos plasmócitos CD138+ com marcadores de resposta humoral. Entretanto, nesse estudo o infiltrado de células B na biópsia do enxerto não foi preditivo de uma pior evolução do rim transplantado. / Introduction: The fragment C4d and the donor specific anti-HLA antibodies (DSA) are markers of the humoral response in rejecting kidney grafts, but the role of B cells in this process is still unclear. In this study we evaluated the correlation between C4d, DSA and B cells in dysfunctional grafts, and their association with morphological features, and graft function and survival. Material and Methods: The staining for C4d, CD20+ B cells and CD138+ plasmocytes were done by immunoperoxidase in 110 kidney graft biopsies for cause. Positivity for CD20 and CD138 were established by ROC curve (≥5 cells/mm2). Serum collected at biopsy were tested for anti-HLA class I and II antibodies. These markers were correlated with clinical and transplant characteristics, Banff histopathology and graft outcomes. Results: C4d deposits and circulating DSA were detected in 100% and 70% of the patients with antibody-mediated rejection (AMR) respectively, and in cases with acute cellular rejection (ACR) in 42% (p<0.001, vs. AMR) and 28% (p=0.003, vs. AMR), respectively. Both markers were positively correlated (r=0.31, p=0.016), and there was also a significant correlation between DSA and plasmocytes CD138+ (r=0.32 p=0.006). CD20 and C138 cells were not siginificantly correlated. Plasmocytes CD138+ predominated in AMR, and were associated with higher pre transplant PRA and DSA positivity, but not with C4d. CD20+ B cells were highly expressed in ACR and in biopsies with interstitial fibrosis and tubular atrophy, in association with more HLA mismatches and re-transplants. Patients with C4d had poorer graft function and survival, and those 9 with DSA + also had a worse graft survival in three years of transplant. CD20 or CD138 cells were not predictive of graft outcomes. In multivariated analysis, only C4d remained a risk factor for graft loss. Conclusion: These results confirm the prognostic value of C4d and circulating DSA for a worse kidney graft outcome, and suggest an association of CD20+ B cells with parameters of cellular rejection whereas CD138+ plasmocytes correlated with markers of the humoral response. However, in this study the B cell infiltrate in graft biopsy was not predictive of adverse outcomes to the transplanted kidney.

Introdução: O fragmento C4d e os anticorpos anti-HLA doador específicos (DSA) são marcadores de resposta humoral em enxertos renais com rejeição, mas o papel das células B nesse processo ainda não é claro. Neste estudo foi avaliada a correlação entre C4d, DSA e células B de enxertos com disfunção e sua associação com aspectos morfológicos, função e sobrevida do rim transplantado. Material e Métodos: A marcação para C4d, células B CD20+ e plasmócitos CD138+ foi realizada por imunoperoxidase em biópsias por indicação de 110 receptores de transplante renal. Positividade para CD20 e CD138 foi definida por curva ROC (≥5 céls./mm2). O soro coletado concomitante a biópsia foi testado para DSA classe I e classe II. Estes marcadores foram correlacionados com dados clínicos e do transplante, a histopatologia de Banff e a evolução do rim transplantado. Resultados: Depósitos de C4d e DSA circulantes foram detectados em 100% e 70% dos pacientes com rejeição mediada por anticorpos (RMA) respectivamente, e nos casos de rejeição aguda celular (RAC) em 42% (p<0,001, vs. RMA) e 28% (p=0,003, vs. RMA). Estes dois marcadores correlacionaram-se positivamente (r=0,31, p=0,016). Houve correlação significativa entre DSA e plasmócitos CD138+ (r=0.32 p=0,006), mas as células CD20 e CD138 não se correlacionaram entre si. As células CD138+ predominaram na RMA, associadas com maior painel pré-transplante e DSA, mas não a C4d, e as células CD20+ predominaram na RAC e nas biópsias com fibrose intersticial/atrofia tubular, associadas a maior incompatibilidade HLA e a retransplantes. Pacientes com C4d+ tiveram pior função e sobrevida do enxerto em três anos de transplante, e aqueles com DSA+ uma pior 7 sobrevida do enxerto. Positividade para CD20 ou CD138 não foi preditiva da função ou sobrevida do enxerto. Na análise multivariada, somente o C4d foi fator de risco para perda do enxerto. Conclusões: Esses resultados confirmam o valor prognóstico do C4d e dos DSA para uma pior evolução do enxerto renal, e sugerem uma associação das células B CD20+ com parâmetros de rejeição celular e dos plasmócitos CD138+ com marcadores de resposta humoral. Entretanto, nesse estudo o infiltrado de células B na biópsia do enxerto não foi preditivo de uma pior evolução do rim transplantado. / Introduction: The fragment C4d and the donor specific anti-HLA antibodies (DSA) are markers of the humoral response in rejecting kidney grafts, but the role of B cells in this process is still unclear. In this study we evaluated the correlation between C4d, DSA and B cells in dysfunctional grafts, and their association with morphological features, and graft function and survival. Material and Methods: The staining for C4d, CD20+ B cells and CD138+ plasmocytes were done by immunoperoxidase in 110 kidney graft biopsies for cause. Positivity for CD20 and CD138 were established by ROC curve (≥5 cells/mm2). Serum collected at biopsy were tested for anti-HLA class I and II antibodies. These markers were correlated with clinical and transplant characteristics, Banff histopathology and graft outcomes. Results: C4d deposits and circulating DSA were detected in 100% and 70% of the patients with antibody-mediated rejection (AMR) respectively, and in cases with acute cellular rejection (ACR) in 42% (p<0.001, vs. AMR) and 28% (p=0.003, vs. AMR), respectively. Both markers were positively correlated (r=0.31, p=0.016), and there was also a significant correlation between DSA and plasmocytes CD138+ (r=0.32 p=0.006). CD20 and C138 cells were not siginificantly correlated. Plasmocytes CD138+ predominated in AMR, and were associated with higher pre transplant PRA and DSA positivity, but not with C4d. CD20+ B cells were highly expressed in ACR and in biopsies with interstitial fibrosis and tubular atrophy, in association with more HLA mismatches and re-transplants. Patients with C4d had poorer graft function and survival, and those 9 with DSA + also had a worse graft survival in three years of transplant. CD20 or CD138 cells were not predictive of graft outcomes. In multivariated analysis, only C4d remained a risk factor for graft loss. Conclusion: These results confirm the prognostic value of C4d and circulating DSA for a worse kidney graft outcome, and suggest an association of CD20+ B cells with parameters of cellular rejection whereas CD138+ plasmocytes correlated with markers of the humoral response. However, in this study the B cell infiltrate in graft biopsy was not predictive of adverse outcomes to the transplanted kidney.

No description available.

Die Entzündungsreaktion der Arthrose wird als eine sekundäre Reaktion auf einen degenerativen Prozeß des Gelenkknorpels angesehen. Die Ursache für die Degeneration kann im Mißverhältnis zwischen Belastbarkeit und Beanspruchung liegen, es können metabolische Störungen (Urämie, Diabetes mellitus) verantwortlich gemacht werden, weswegen von sekundärer Arthrose gesprochen wird. Die Ursache der primären Arthrose bleibt unbekannt. Es kann als bewiesen angesehen werden der Zusammenhang mit Alter und Geschlecht der Patienten, denn Arthrose ist in der Regel eine Erkrankung jenseits des fünfzigsten Lebensjahres und betrifft vornehmlich Frauen. In der vorliegenden Arbeit wurde die Synovialis von 20 Patienten aufgearbeitet und hinsichtlich des enthaltenen entzündlichen Infiltrates untersucht. Unter Anwendung der indirekten Immunperoxidase Technik und der indirekten Immunfluoreszenz Technik wurde die Expression der Antigene CD 20, CD 23, CD 40, CD 27, IgG, IgA, IgM, Kappa, Lambda, CD 3, CD 4, CD 8, Ki M4, CD 68, Ki 67 sowie die Expression der Cytokine IL 2 und IL 10 analysiert. Die Synovialmembran zeigte histologisch eine Verbreiterung der Deckzellschicht, Knorpelfragmente innerhalb der Synovialmembran und ein insgesamt schwach ausgeprägtes entzündliches Infiltrat. In lediglich drei von 20 Fällen fand sich eine stärkere entzündliche Infiltration. Diese entzündlichen Infiltrate wiesen eine perivaskuläre Verteilung auf. Am häufigsten wurden in gefäßnahen Regionen B Lymphozyten identifiziert, Plasmazellen wiesen in der Regel einen deutlich größeren Abstand zum Gefäß auf. Unter den nachgewiesenen Plasmazellen fand sich eine prädominante Expression an IgG bei ausgewogener Anwesenheit sowohl der Kappa- als auch der Lambda- Leichtketten. T Lymphozyten waren ebenfalls zirkulär um die Gefäße anzutreffen und zeigten eine prädominante Interleukin 10 Expression. Lymphozytäre Aggregate, mit follikelähnlicher Struktur ließen sich in lediglich in 4 von 20 Fällen nachweisen. Makrophagen waren sowohl perivaskulär als auch in der Deckzellschicht nachweisbar. Ki M4 positive Retikulumzellen (FDC) waren dagegen nur in einem von 20 Fällen nachweisbar. Alle Zellpopulationen der Membrana synovialis wiesen nur eine schwache Proliferationsaktivität auf. Das Fehlen von dem Keimzentrum des Lymphfollikels vergleichbaren Strukturen, die deutliche Abwesenheit von Ki M4 positiver FDC's sowie die schwache Expression von Ki 67, sprechen trotz Anwesenheit der ebenfalls zur Antigenpräsentation befähigten Makrophagen gegen eine Einwanderung und Maturation nativer B Lymphozyten in die Membrana Synovialis. Wandern dagegen Gedächtniszellen in die Membrana synovialis ein, so ist eine Maturation mit Follikelbildung nicht mehr notwendig. Unter der Mithilfe von T Lymphozyten und Makrophagen können die B Lymphozyten zu Plasmazellen differenzieren. T Lymphozyten zeichnen sich ebenfalls durch eine starke perivaskuläre Verteilung aus. Dabei ist die Expression von IL 10 prädominant, was sich als eine Immunantwort von TH2-Typus interpretieren läßt. Diese ermöglicht eine Differenzierung der B Lymphozyten zu Plasmazellen. Reife B Lymphozyten, die unter dem Einfluß einer TH2 Subpopulation von CD 4 positiven T Lymphozyten ohne Keimzentrum zu Plasmazellen differenzieren, könnten ein Grund dafür sein, daß follikuläre Strukturen fehlen. Vorgereifte B Lymphozyten benötigen auch keine inflammatorisch hochpotenten Zytokine um eine schnelle Reifung und eine Immunantwort zu ermöglichen. Dies könnte ein Grund sein, warum die entzündliche Reaktion bei Arthrose so schwach ausgeprägt ist. / Inflammation in osteoarthritis is a secondary reaction to a degenerating process of the articular cartilage. Cause of Degeneration can be a disproportion of mechanical stress and resistance or metabolic diseases like diabetes mellitus. This kind of osteoarthritis is called "secondary osteoarthritis". Primary osteoarthritis has an unknown cause. Age and sex of the patient are a predictor for osteoarthritis, hense it is a disease of people above the age of 50 and more often it is found in women than in men. This paper investigated the synovial membranes of twenty patients to characterize the inflammatory Infiltrate. It characterized the cell surface antigen CD 20, CD 23, CD 40, CD 27, CD 3, CD 4, CD 8, Ki M4, CD 68, the antibodies IgG, IgA, IgM, Kappa, Lambda, the proliferating antigen Ki 67 and the expression profile of the cytokines IL 2 and IL 10 by using immunohistochemical staining (indirect immunoperoxidase technique and indirect immunofluorescence technique) with monoclonal antibodies. The synovial membrane shows in histology a dissemination of cover cells, fragments of cartilage and a slight expression of inflammatory infiltrate with a perivascular allocation. In only three of twenty cases we detected stronger inflammatory infiltrates. Most of the perivascular cells express CD 20. They are B lymphocytes. Plasma cells have more distance to the blood vessels and showed a predominant expression of IgG. T-lymphocytes were also detected perivascular. The expression of IL 10 was predominant. Lymphocytes aggregates like lymph follicle were detected in four of twenty cases. Macrophages were proved perivascular as well as in the cover cells. Ki M4 positive reticulum cells were found in only one of twenty cases. All kind of cells in the synovial membrane showed a low proliferation activity. The absence of germinal centers or comparable structures, the low expression of Ki M4 and Ki 67 speak against the immigration and maturation of native B lymphocytes in the synovial membrane. Memory B-lymphocytes don't need germinal centers or compatible structures for maturation, they can mature to plasma cells by help of T-lymphocytes, macrophages or other B-lymphocytes. It is more probably that the detected B lymphocytes are memory cells. The perivascular T lymphocytes in combination with the predominant expression of IL 10 may be interpreted as a TH2 immune reaction. This supports the maturation of B-lymphocytes to plasma cells. The maturation of memory B-lymphocytes under influence of TH2 immune reaction can be the reason for the missing of germinal centers or comparable structures. Matured B-lymphocytes don't need high-grade inflammatory cytokines for quick immune response. This is the possible reason for the low-grade inflammatory reaction of osteoarthritis.

A presença de uma inflamação crônica no músculo, a associação com outras doenças e a presença de auto-anticorpos, sugere o envolvimento de um mecanismo autoimune na patogênese da DMJ. Trinta e sete fragmentos musculares de pacientes com o diagnóstico de DMJ foram estudados com o objetivo de avaliar a expressão de MHC classes I e II, C5b-9 e fenotipagem das células inflamatórias CD4, CD8, CD20 e CD68 em tecido muscular e correlacionar com os principais parâmetros clínicos, laboratoriais, histológicos e terapêuticos desta doença. Os achados foram comparados à expressão em oito fragmentos musculares de pacientes com polimiosite (PM), cinco de dermatomiosite (DM) e quatro de distrofia. As expressões de MHC-I, MHC-II e C5b-9 foram identificadas por imunohistoquímica, através da técnica de imunoperoxidase StreptABComplex/HRP; as células CD20 e CD68, pelo sistema LSAB+ e CD4 e CD8, pela técnica EnVision-AP. A expressão de MHC-I apresentou positividade em 97,2% dos casos, enquanto que a expressão de MHC-II foi observada em apenas 21,6% dos casos. C5b-9 (83,8% de positividade), correlacionou-se com a presença de calcinose e envolvimento cardíaco. A presença de linfócitos CD4 (81,1% de positividade), CD8 (86,5% de positividade) e CD20 (62,2 % de positividade), e CD68 (97,2% de positividade) correlacionaram-se com o grau de inflamação observada na histologia muscular. A presença de CD4 e CD68, e marcação de C5b-9 também se correlacionaram com a intensidade de fraqueza muscular, e laboratorialmente, CD4 correlacionou-se com níveis elevados de CK e CD20 com DHL. Na DMJ observou-se maior expressão de C5b-9, CD4 e CD8 e menor expressão de MHC-I e II em comparação à DM e PM. A expressão destes marcadores foi sempre menor na distrofia. A expressão de MHC-I, adjuvante ao envolvimento dos linfócitos CD4 e CD8, sugere um mecanismo inicial celular citotóxico relacionado a maior gravidade do envolvimento muscular. A concomitância da maior expressão de C5b-9 foi um fator preditivo de comprometimento sistêmico e demanda de terapêutica imunossupresssora. Os resultados deste estudo apontam para o papel do MHC-I e II, C5b-9, CD4, CD8, CD20 e CD68 na patogênese da DMJ / The presence of chronic muscle inflammation, in association with other diseases and seric autoantibodies in JDM patients, suggest the involvement of an autoimmune mechanism in the pathogenesis of this inflammatory myopathy. Thirty seven muscle biopsy specimens from patients with JDM were analyzed in order to assess the expression of MHC-I and II, C5b-9, CD4, CD8, CD20 and CD68 and to correlate with the clinical, laboratorial, histological and therapeutical parameters. These findings were compared to the expression in five dermatomyositis (DM), eight polymyositis (PM) and four dystrophy cases. Immunohistochemical reactions for MHC-I and II and C5b-9 (StreptABCcomplex/HRP), CD4, CD8 (EnVision-AP) and CD20, CD68 (LSAB+) were evaluated. MHC-I expression was positive in 97.2% of the cases, whilst MHC-II was positive in only 21.6% of the cases. C5b-9 expression (positivity of 83.8%) correlated with calcinosis and cardiac involvement. The presence of lymphocytes CD4 (positivity of 81.1%), CD8 (positivity of 86.5%), CD20 (positivity of 62.2%), and CD68 (positivity of 97.2%) correlated with inflammation in muscular histology. The presence of CD4 and CD8 and expression of C5b-9 also correlated with the severity of muscle weakness, and CD4 expression correlated with serum levels of CK and CD20 with LDH. In JDM, the expressions of C5b-9, CD4 and CD8 were statistically more significant when compared to PM and DM, while expressions of MHC-I and II were lower in JDM. All expressions were lower in dystrophy. MHC-I expression, adjuvant to the presence of CD4 and CD8 lymphocytes, corroborates the involvement of the cytotoxic cellular mechanism of muscular lesion in JDM, which correlates to severity. Concomitantly, C5b-9 expression was a predictive factor of systemic involvement and of the need for imunossupressive treatment. The results of this study indicate for the function of MHC-I and II, C5b-9, CD4, CD8, CD20 e CD68 at JDM pathogenesis

A presença de uma inflamação crônica no músculo, a associação com outras doenças e a presença de auto-anticorpos, sugere o envolvimento de um mecanismo autoimune na patogênese da DMJ. Trinta e sete fragmentos musculares de pacientes com o diagnóstico de DMJ foram estudados com o objetivo de avaliar a expressão de MHC classes I e II, C5b-9 e fenotipagem das células inflamatórias CD4, CD8, CD20 e CD68 em tecido muscular e correlacionar com os principais parâmetros clínicos, laboratoriais, histológicos e terapêuticos desta doença. Os achados foram comparados à expressão em oito fragmentos musculares de pacientes com polimiosite (PM), cinco de dermatomiosite (DM) e quatro de distrofia. As expressões de MHC-I, MHC-II e C5b-9 foram identificadas por imunohistoquímica, através da técnica de imunoperoxidase StreptABComplex/HRP; as células CD20 e CD68, pelo sistema LSAB+ e CD4 e CD8, pela técnica EnVision-AP. A expressão de MHC-I apresentou positividade em 97,2% dos casos, enquanto que a expressão de MHC-II foi observada em apenas 21,6% dos casos. C5b-9 (83,8% de positividade), correlacionou-se com a presença de calcinose e envolvimento cardíaco. A presença de linfócitos CD4 (81,1% de positividade), CD8 (86,5% de positividade) e CD20 (62,2 % de positividade), e CD68 (97,2% de positividade) correlacionaram-se com o grau de inflamação observada na histologia muscular. A presença de CD4 e CD68, e marcação de C5b-9 também se correlacionaram com a intensidade de fraqueza muscular, e laboratorialmente, CD4 correlacionou-se com níveis elevados de CK e CD20 com DHL. Na DMJ observou-se maior expressão de C5b-9, CD4 e CD8 e menor expressão de MHC-I e II em comparação à DM e PM. A expressão destes marcadores foi sempre menor na distrofia. A expressão de MHC-I, adjuvante ao envolvimento dos linfócitos CD4 e CD8, sugere um mecanismo inicial celular citotóxico relacionado a maior gravidade do envolvimento muscular. A concomitância da maior expressão de C5b-9 foi um fator preditivo de comprometimento sistêmico e demanda de terapêutica imunossupresssora. Os resultados deste estudo apontam para o papel do MHC-I e II, C5b-9, CD4, CD8, CD20 e CD68 na patogênese da DMJ / The presence of chronic muscle inflammation, in association with other diseases and seric autoantibodies in JDM patients, suggest the involvement of an autoimmune mechanism in the pathogenesis of this inflammatory myopathy. Thirty seven muscle biopsy specimens from patients with JDM were analyzed in order to assess the expression of MHC-I and II, C5b-9, CD4, CD8, CD20 and CD68 and to correlate with the clinical, laboratorial, histological and therapeutical parameters. These findings were compared to the expression in five dermatomyositis (DM), eight polymyositis (PM) and four dystrophy cases. Immunohistochemical reactions for MHC-I and II and C5b-9 (StreptABCcomplex/HRP), CD4, CD8 (EnVision-AP) and CD20, CD68 (LSAB+) were evaluated. MHC-I expression was positive in 97.2% of the cases, whilst MHC-II was positive in only 21.6% of the cases. C5b-9 expression (positivity of 83.8%) correlated with calcinosis and cardiac involvement. The presence of lymphocytes CD4 (positivity of 81.1%), CD8 (positivity of 86.5%), CD20 (positivity of 62.2%), and CD68 (positivity of 97.2%) correlated with inflammation in muscular histology. The presence of CD4 and CD8 and expression of C5b-9 also correlated with the severity of muscle weakness, and CD4 expression correlated with serum levels of CK and CD20 with LDH. In JDM, the expressions of C5b-9, CD4 and CD8 were statistically more significant when compared to PM and DM, while expressions of MHC-I and II were lower in JDM. All expressions were lower in dystrophy. MHC-I expression, adjuvant to the presence of CD4 and CD8 lymphocytes, corroborates the involvement of the cytotoxic cellular mechanism of muscular lesion in JDM, which correlates to severity. Concomitantly, C5b-9 expression was a predictive factor of systemic involvement and of the need for imunossupressive treatment. The results of this study indicate for the function of MHC-I and II, C5b-9, CD4, CD8, CD20 e CD68 at JDM pathogenesis

Ces dernières années, grâce aux progrès réalisés dans l'humanisation des anticorps monoclonaux recombinants (Acm-r), ceux-ci ont vu leur utilisation thérapeutique s'accroître, notamment dans le traitement du cancer. Parmi ces Acm-r, le rituximab (MabThera®, Rituxan®) est le premier à avoir obtenu une autorisation de mise sur le marché en Europe et aux Etats-Unis. Il s'agit d'un anticorps chimérique de type IgG1 kappa dirigé contre l'antigène de surface CD20 exprimé par plus de 95% des cellules lymphoïdes B. Le rituximab utilisé seul ou en association avec de la chimiothérapie a montré son efficacité dans le traitement des lymphomes de faible et de haute malignité. Néanmoins, lorsqu'il est utilisé en monothérapie, 30 à 50% des patients ne répondent pas au traitement. Plusieurs hypothèses ont été évoquées pour expliquer cette variabilité de réponse, parmi lesquelles l'importance de la masse tumorale, un faible niveau d'expression du CD20, la présence de formes solubles de CD20 ou encore de faibles concentrations sériques de rituximab. Ainsi, l'exposition au médicament et la masse tumorale pourraient être des facteurs de variabilité thérapeutique à prendre en compte pour optimiser individuellement le traitement des patients atteints de lymphome malin non hodgkinien.<br /><br />L'objectif général de ce travail de thèse a été d'analyser les rôles respectifs du volume tumoral et des paramètres pharmacocinétiques dans la réponse au rituximab en utilisant des moyens d'imagerie adaptés aux modèles murins et à la cancérologie.<br /><br />Dans une première partie de mise au point du modèle, nous avons utilisé une lignée lymphomateuse T (EL4) syngénique de souris C57Bl6J, transduite par le CD20 humain que nous avons transfectée avec le gène de la luciférase (EL4-huCD20-Luc). Nous avons ensuite défini les conditions expérimentales (nombre de cellules, voie d'administration, dose de luciférine de potassium, fond génétique, périodicité des examens) permettant de reproduire chez la souris le développement d'un lymphome agressif et disséminé à larges cellules B létal dans un délai de 30 à 40 jours après inoculation. Nous avons mis au point une méthode de quantification de l'intensité de bioluminescence des foyers tumoraux en prenant en compte le coefficient d'absorption de la lumière propre à la localisation anatomique de chaque tumeur lymphomateuse. <br /><br />Dans une seconde partie nous avons étudié l'effet thérapeutique du rituximab sur ce lymphome. Une seule injection de rituximab à dose progressivement croissante (de 150 µg à 1000 µg) a été réalisée 13 jours après l'inoculation des cellules lymphomateuses (temps nécessaire au développement d'un lymphome quantifiable par imagerie de bioluminescence). La concentration de rituximab circulant a été évaluée par une méthode ELISA adaptée à l'analyse de faibles volumes de plasma et à un modèle murin. Dans ce modèle, nous avons montré qu'il existait une relation entre la dose administrée et la survie des souris, la totalité des souris étant survivantes à la dose de 1000 µg. C'est à 500 µg que nous avons retrouvé la plus grande variabilité de réponse au rituximab avec environ 23% de souris totalement guéries, 59% en réponse partielle et 18% avec une maladie en progression. Pour l'ensemble des souris recevant cette dose, nous avons déterminé précisément le volume tumoral au moment de l'injection du rituximab et évalué les concentrations de rituximab au décours du traitement. Nous avons ainsi montré qu'il existait une relation significative entre le volume tumoral au moment de l'injection et la réponse au rituximab ; les souris présentant les plus faibles volumes tumoraux ayant une meilleure réponse et une survie prolongée. L'analyse de l'évolution des concentrations de rituximab au cours du temps nous a permis de montrer une très grande variabilité d'exposition à l'anticorps semblable à l'observation faite chez l'homme. Nous avons modélisé les concentrations de rituximab et la progression des foyers tumoraux par la construction d'un modèle concentration/effet (PK-PD) nous ayant permis de démontrer l'existence d'une relation entre l'efficacité du rituximab et le volume tumoral avant traitement.<br /><br />Enfin dans un troisième volet nous avons utilisé le modèle cellulaire EL4-huCD20-Luc afin d'évaluer in vitro l'usage de particules d'oxydes de gadolinium ou de particules d'oxydes de gadolinium et de bore. Nous avons montré les qualités d'agents de contraste de ces particules pour l'imagerie à résonance magnétique. Nous avons aussi analysé l'important effet rayonnant de ces particules lors d'une irradiation sous un faisceau de neutrons après une étape d'internalisation des particules au sein des cellules.